NeuroSense Therapeutics Ltd.
NASDAQ: NRSNW0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- NASDAQ Capital Market
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Alon Ben-Noon
- Employees
- 17
- Headquarters
- Herzliya, Israel
- IPO year
- 2021
- Market cap
- $1.8M
- Website
- https://www.neurosense-tx.com
Loading NRSNW…
Loading profile data…Frequently asked questions about NRSNW
What does NeuroSense Therapeutics Ltd. (NRSNW) do?
NeuroSense Therapeutics Ltd. is an Israeli clinical-stage biotechnology firm dedicated to pioneering novel therapies for severe neurodegenerative conditions. Its most advanced investigational asset is PrimeC, an innovative oral compound specifically engineered to address amyotrophic lateral sclerosis (ALS). Beyond its lead program, the company b...
Where does NRSNW trade?
NeuroSense Therapeutics Ltd. (NRSNW) trades on the NASDAQ Capital Market.
What sector is NRSNW in?
NeuroSense Therapeutics Ltd. (NRSNW) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of NeuroSense Therapeutics Ltd.?
Alon Ben-Noon is the chief executive officer of NeuroSense Therapeutics Ltd. (NRSNW).
Where is NeuroSense Therapeutics Ltd. headquartered?
NeuroSense Therapeutics Ltd. is headquartered in Israel.
Does NRSNW pay a dividend?
NeuroSense Therapeutics Ltd. (NRSNW) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did NRSNW go public?
NeuroSense Therapeutics Ltd. (NRSNW) completed its initial public offering in 2021.